Hepatic steatosis: a risk factor for increased COVID-19 prevalence and severity—a computed tomography study
Open Access
- 12 July 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Egyptian Liver Journal
- Vol. 11 (1), 1-9
- https://doi.org/10.1186/s43066-021-00131-6
Abstract
Around 25% of the world population was affected by the metabolic-related fatty liver disorder. Hepatic steatosis is frequently observed in conjunction with hypertension, obesity comorbidities, and diabetes. We evaluate the hepatic steatosis frequency found in chest CT exams of COVID-19-positive cases compared to non-infected controls and evaluate the related increased prevalence and severity of COVID. Our research includes 355 subjects, 158 with positive PCR for COVID-19 (case group) and 197 with negative PCR and negative CT chest (control group). The mean age in the positive group was 50.6 ± 16 years, and in the control, it was 41.3 ± 16 years (p < 0.001). Our study consists of 321 men (90.5%) and 34 women (9.5%). The number of males in both cases and control groups was greater. In the case group, 93% men vs. 6.9% women, while in controls, 88.3% men vs.11.6% women, p < 0.001. CT revealed normal results in 55.5% of individuals (i.e., CORADs 1) and abnormal findings in 45.5% of participants (i.e., CORADs 2–5). In abnormal scan, CO-RADs 2 was 13.92%, while CO-RADs 3–4 were 20.89% of cases. CO-RADs 5 comprised 65.19% of all cases. Approximately 42.6% of cases had severe disease (CT score ≥ 20), all of them were CO-RADs 5. The PCR-positive class had a greater prevalence of hepatic steatosis than controls (28.5% vs.12.2%, p < 0.001). CO-RADs 2 represented 11.1%, CO-RADs 3–4 represented 15.6%, and CO-RADs 5 represented 73.3% in the hepatic steatosis cases. The mean hepatic attenuation value in the case group was 46.79 ± 12.68 and in the control group 53.34 ± 10.28 (p < 0.001). When comparing patients with a higher severity score (CT score ≥ 20) to those with non-severe pneumonia, it was discovered that hepatic steatosis is more prevalent (73.2% vs. 26.8%). Steatosis was shown to be substantially more prevalent in COVID-19-positive individuals. There is a relation among metabolic syndrome, steatosis of the liver, and obesity, as well as the COVID-19 severity.Keywords
This publication has 55 references indexed in Scilit:
- Characterization of adipose-derived stem cells from subcutaneous and visceral adipose tissues and their function in breast cancer cellsOncotarget, 2015
- Interaction of obesity and infectionsObesity Reviews, 2015
- Diagnosis of hepatic steatosis by contrast-enhanced abdominal computed tomographyRadiologia Brasileira, 2013
- Obesity and AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Detection of Hepatic Steatosis on Contrast-Enhanced CT Images: Diagnostic Accuracy of Identification of Areas of Presumed Focal Fatty SparingAmerican Journal of Roentgenology, 2012
- Impact of Visceral Adiposity Measured by Abdominal Computed Tomography on Pulmonary FunctionJournal of Korean Medical Science, 2011
- Hepatic Steatosis (Fatty Liver Disease) in Asymptomatic Adults Identified by Unenhanced Low-Dose CTAmerican Journal of Roentgenology, 2010
- Imaging-based Quantification of Hepatic Fat: Methods and Clinical ApplicationsRadioGraphics, 2009
- Imaging Features of Perivascular Fatty Infiltration of the Liver: Initial ObservationsRadiology, 2005
- Nonalcoholic Fatty Liver DiseaseThe New England Journal of Medicine, 2002